Global Respiratory Inhalers Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Devices;
Nebulizers (Compressed, Mesh, and Ultrasonic), Dry Powder Inhaler (Single Unit Dose Inhaler, Multi Dose Inhaler, and Multi-Unit Dose Inhaler), and Metered Dose Inhaler.By Product;
Dry Powder Inhaler, Metered Dose Inhaler, and Others.By Therapeutic Application;
Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, and Cystic Fibrosis.By End User;
Hospitals & Clinics, Respiratory Care Center, Academic and Research Institutes, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Respiratory Inhalers Market (USD Million), 2021 - 2031
In the year 2024, the Global Respiratory Inhalers Market was valued at USD 7,068.77 million. The size of this market is expected to increase to USD 10,741.63 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.2%.
The Global Respiratory Inhalers Market serves as a vital component within the broader spectrum of respiratory care, providing effective and convenient delivery of medication for various respiratory conditions. Inhalers are indispensable tools in the management of diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, offering patients rapid relief from symptoms and helping to maintain long-term respiratory health.
This market segment encompasses a diverse array of inhaler devices, ranging from metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) to soft mist inhalers (SMIs) and nebulizers. Each type of inhaler is designed to deliver specific formulations of medication directly into the lungs, targeting the underlying respiratory inflammation, bronchoconstriction, or infection associated with various respiratory conditions.
The global respiratory inhalers market is characterized by ongoing innovation and advancements in inhaler technology, aimed at improving drug delivery efficiency, enhancing patient adherence, and minimizing adverse effects. Manufacturers continuously strive to develop inhaler devices that are user-friendly, portable, and capable of delivering precise doses of medication, thereby optimizing therapeutic outcomes and improving the quality of life for patients with respiratory disorders.
Several factors drive the growth of the global respiratory inhalers market, including the increasing prevalence of respiratory diseases, rising awareness of the importance of early diagnosis and effective treatment, and the growing demand for convenient and portable drug delivery solutions. Demographic trends such as aging populations and urbanization contribute to the rising burden of respiratory conditions worldwide, further fueling the demand for respiratory inhalers.
In addition to serving as frontline treatments for acute respiratory symptoms, inhalers also play a crucial role in preventive care and long-term management of chronic respiratory diseases. By providing patients with easy access to inhaler devices and educating them on proper inhaler technique and medication adherence, healthcare providers can empower individuals to take control of their respiratory health and minimize the impact of respiratory conditions on their daily lives.
Global Respiratory Inhalers Market Recent Developments
-
In December 2020, OMRON Healthcare introduced WheezeScan for children suffering from Asthma to accurately detect the presence of wheezing in young children and to remove the unpredictability of potential misdiagnosis.
-
In March 2021, in the United States and Mexico, AstraZeneca PLC initiated a Phase III clinical trial to assess the effectiveness and safety of budesonide/glycopyrronium/formoterol inhalers in adolescents and adults with chronic asthma inadequately controlled with standard care. The will trial will be completed in September 2023.
Segment Analysis
Devices play a key role in the segmentation, as this category includes the types of inhalers designed to deliver medication to the lungs. Key devices in the market include Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), and Soft Mist Inhalers. DPIs are favored for their ease of use, requiring patients to simply inhale deeply to activate the medication release. MDIs are widely used for their ability to provide precise dosages, though they often require coordination for optimal use. Soft mist inhalers combine features from both DPIs and MDIs, offering an alternative delivery method that provides a fine mist for deep lung penetration and better medication absorption.
Product segmentation focuses on the formulation of the medication delivered by these inhalers. This includes bronchodilators, which help relax airway muscles for easier breathing, and corticosteroids, used to reduce inflammation in the airways. Combination inhalers, which blend both bronchodilators and corticosteroids, are often prescribed for long-term management of chronic respiratory conditions like COPD and asthma. The different product types cater to various patient needs and treatment plans, influencing both market growth and user preference.
Therapeutic Application categorizes the market based on the medical conditions that the inhalers are designed to treat. This includes asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and other respiratory issues. Asthma and COPD are the leading therapeutic areas for inhaler use, contributing significantly to market demand. These conditions require continuous treatment to manage symptoms and prevent exacerbations, making inhalers essential tools in maintaining respiratory health.
End User segmentation is essential in understanding where and how these devices are used in healthcare settings. Hospitals and clinics are major users of respiratory inhalers, providing immediate and long-term care for patients with acute or chronic conditions. Homecare settings are seeing growth due to the rising preference for remote management of respiratory conditions, allowing patients to use inhalers comfortably at home. Specialty clinics and research institutions also play a role in the market, contributing to the development and usage of advanced inhalation technologies for clinical trials and experimental treatment.
Geography significantly impacts the market as it reflects regional healthcare infrastructure, economic conditions, and access to medical technologies. North America and Europe remain dominant in the market due to their well-established healthcare systems, high prevalence of chronic respiratory diseases, and advanced medical technology infrastructure. The Asia-Pacific region is expected to witness significant growth due to increased healthcare investments, rising awareness of respiratory conditions, and a growing elderly population. Latin America, the Middle East, and Africa show potential for growth as healthcare systems improve and access to medical devices expands.
Global Respiratory Inhalers Segment Analysis
In this report, the Global Respiratory Inhalers Market has been segmented by Devices, Product, Therapeutic Application, End User, and Geography.
Global Respiratory Inhalers Market, Segmentation by Devices
The Global Respiratory Inhalers Market has been segmented by Devices into Nebulizers (Compressed, Mesh, and Ultrasonic), Dry Powder Inhaler (Single Unit Dose Inhaler, Multi Dose Inhaler, and Multi-Unit Dose Inhaler), and Metered Dose Inhaler.
Nebulizers represent a pivotal category within the respiratory inhalers market, comprising a range of devices designed to convert liquid medication into fine aerosol particles for inhalation. This category encompasses compressed air nebulizers, mesh nebulizers, and ultrasonic nebulizers, each employing different technologies to generate aerosols with varying particle sizes and delivery rates. Nebulizers are particularly favored for delivering medications to patients with severe respiratory conditions, infants, and individuals unable to effectively use traditional inhaler devices.
Dry Powder Inhalers (DPIs) constitute another significant segment in the respiratory inhalers market, offering convenient and portable options for delivering powdered medications directly into the lungs. DPIs are further classified into single-unit dose inhalers, multi-dose inhalers, and multi-unit dose inhalers, reflecting variations in dose administration, storage capacity, and medication formulation. DPIs are widely utilized for the treatment of asthma, COPD, and other respiratory diseases, providing patients with rapid and effective relief from symptoms and improving medication adherence.
Metered Dose Inhalers (MDIs) represent a classic and widely used category of inhaler devices, delivering metered doses of medication in aerosol form with each actuation. MDIs consist of a pressurized canister containing the medication formulation, along with a metering valve and mouthpiece for inhalation. These devices offer precise and consistent drug delivery, making them suitable for managing acute and chronic respiratory conditions such as asthma and COPD. Additionally, MDIs are valued for their portability, ease of use, and versatility in delivering a wide range of medications, including bronchodilators, corticosteroids, and combination therapies.
Global Respiratory Inhalers Market, Segmentation by Product
The Global Respiratory Inhalers Market has been segmented by Product into Dry Powder Inhaler, Metered Dose Inhaler, and Others.
Dry Powder Inhalers (DPIs) are popular for their ease of use and effectiveness in delivering medication directly to the lungs. They rely on the patient's inhalation to disperse the powder medication, making them suitable for patients who have the capacity to inhale deeply and effectively. DPIs do not require the coordination needed with MDIs, making them a favorable option for patients who may struggle with using pressurized inhalers correctly. Their design is also compact and portable, providing convenience for daily use. DPIs are commonly prescribed for chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), where long-term medication management is essential.
Metered Dose Inhalers (MDIs) are among the most widely used types of inhalers for treating respiratory ailments. MDIs deliver a specific dose of medication in a pressurized spray, allowing for consistent and accurate dosing. The patient needs to coordinate their inhalation with the activation of the device, which can be challenging for some, especially children and the elderly. However, modern MDIs often come with built-in spacers or holding chambers to aid in the delivery of medication and improve coordination. They are highly effective for quick relief in acute situations and are commonly prescribed for both asthma and COPD management, ensuring that patients receive the exact dose needed to manage symptoms effectively.
The Others category includes various innovative and less common inhalation devices that contribute to the overall respiratory device market. This category can include soft mist inhalers, nebulizers, and combination devices that integrate multiple features. Soft mist inhalers create a fine mist that allows for deep lung penetration, and they are designed for ease of use, making them ideal for patients who may struggle with traditional MDIs. Nebulizers are devices that convert liquid medication into a mist that can be inhaled, suitable for patients with severe respiratory conditions or those who require continuous medication. Combination devices might include features like dose counters or dual-chambered systems that mix medication at the time of use for better effectiveness.
Global Respiratory Inhalers Market, Segmentation by Therapeutic Application
The Global Respiratory Inhalers Market has been segmented by Therapeutic Application into Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, and Cystic Fibrosis.
Asthma stands as a prominent therapeutic application within the respiratory inhalers market, representing a chronic inflammatory condition characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. Inhaler therapy plays a central role in the management of asthma, providing bronchodilator medications such as beta-agonists and corticosteroids to alleviate symptoms, reduce airway inflammation, and prevent asthma exacerbations. Inhalers, including metered dose inhalers and dry powder inhalers, offer rapid and targeted delivery of medication directly into the lungs, enabling patients to achieve optimal asthma control and improve their quality of life.
Chronic Obstructive Pulmonary Disease (COPD) constitutes another significant therapeutic application in the respiratory inhalers market, encompassing a group of progressive lung diseases such as emphysema and chronic bronchitis. Inhaler therapy serves as a cornerstone of COPD management, delivering bronchodilators, corticosteroids, and combination therapies to relieve symptoms, improve lung function, and reduce exacerbations. Metered dose inhalers, dry powder inhalers, and nebulizers are commonly used in COPD treatment, offering patients personalized and effective options for managing their condition and enhancing respiratory function.
Pulmonary Arterial Hypertension (PAH) represents a less common but clinically significant therapeutic application for inhaler therapy, characterized by elevated blood pressure in the arteries of the lungs, leading to progressive pulmonary vascular remodeling and right heart failure. Inhalers containing vasodilator medications such as prostacyclin analogs and endothelin receptor antagonists are utilized in PAH management to reduce pulmonary vascular resistance, improve exercise capacity, and prolong survival. These inhalers provide targeted delivery of medication to the pulmonary vasculature, offering patients symptomatic relief and hemodynamic stabilization in PAH.
Cystic Fibrosis completes the spectrum of therapeutic applications in the respiratory inhalers market, comprising a hereditary disorder characterized by abnormal mucus production, chronic airway inflammation, and recurrent respiratory infections. Inhaler therapy plays a crucial role in cystic fibrosis management, delivering mucolytic agents, bronchodilators, antibiotics, and other medications to facilitate airway clearance, reduce mucus viscosity, and prevent infection. Nebulizers, dry powder inhalers, and soft mist inhalers are commonly employed in cystic fibrosis treatment, providing patients with targeted and efficient delivery of medication to address the underlying pathophysiology of the disease.
Global Respiratory Inhalers Market, Segmentation by End Users
The Global Respiratory Inhalers Market has been segmented by End Users into Hospitals & Clinics, Respiratory Care Center, Academic and Research Institutes, and Others.
Hospitals & Clinics are significant end users of respiratory devices, given their critical need to provide comprehensive care for patients with acute and chronic respiratory conditions. These healthcare facilities use a range of respiratory devices, such as ventilators, nebulizers, and inhalers, to manage both emergency and long-term respiratory care. Hospitals and clinics require devices that can handle high patient volumes, ensure accurate dosing, and support critical care needs, particularly in intensive care units (ICUs) and emergency departments where rapid intervention is crucial for patient survival.
Respiratory Care Centers are specialized facilities focused exclusively on diagnosing and treating respiratory conditions. These centers are essential for managing patients with chronic conditions such as chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea. Respiratory care centers use advanced equipment like CPAP machines, oxygen concentrators, and high-end ventilators to provide specialized care. Their expertise in respiratory treatments ensures better patient outcomes through comprehensive monitoring and personalized treatment plans tailored to individual needs.
Academic and Research Institutes play a critical role in the respiratory devices market by conducting research and development (R&D) to advance technology and improve patient care methods. These institutions contribute to the development of innovative solutions and new therapies in the respiratory space. Research centers may use respiratory devices for experimental purposes, clinical trials, and medical studies that inform clinical practice and regulatory guidelines. Their work supports the continuous evolution of respiratory care and promotes advancements that benefit both patients and the medical community at large.
Others in the end-user category include non-traditional settings such as home care environments, rehabilitation centers, and specialized nursing homes. The growing trend of home-based care, driven by the increased demand for patient-centered treatment and advancements in portable respiratory technology, has amplified the use of devices like portable oxygen concentrators and CPAP machines. Rehabilitation centers also use respiratory devices to support recovery and physical therapy for patients with respiratory issues or conditions that affect lung function.
Global Respiratory Inhalers Market, Segmentation by Geography
In this report, the Global Respiratory Inhalers Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Respiratory Inhalers Market Share (%), by Geographical Region, 2024
North America stands as a prominent region in the global respiratory inhalers market, characterized by advanced healthcare systems, high healthcare spending, and a significant prevalence of respiratory diseases such as asthma and COPD. The region is home to leading manufacturers of inhaler devices and pharmaceutical companies specializing in respiratory therapeutics, driving innovation and market growth. Favorable reimbursement policies and strong patient awareness contribute to the widespread adoption of inhaler therapy in North America.
Europe represents another key region in the respiratory inhalers market, comprising diverse healthcare systems across countries with varying healthcare priorities and regulatory environments. The region is characterized by a high prevalence of asthma and COPD, necessitating robust respiratory care infrastructure and access to a wide range of inhaler devices. Europe is a hub for respiratory research and development, fostering collaborations between academia, industry, and healthcare providers to advance inhaler technology and improve patient outcomes.
The Asia Pacific region emerges as a rapidly growing market for respiratory inhalers, driven by demographic trends such as urbanization, industrialization, and changing lifestyles leading to increased pollution and respiratory diseases. Countries in Asia Pacific, including China, India, and Japan, witness a rising burden of asthma, COPD, and other respiratory conditions, fueling demand for inhaler devices and respiratory care solutions. Market expansion efforts by multinational companies and investments in healthcare infrastructure contribute to the growth of the respiratory inhalers market in Asia Pacific.
The Middle East and Africa region present unique opportunities and challenges in the respiratory inhalers market, characterized by diverse healthcare landscapes, socioeconomic disparities, and varying levels of healthcare access. While some countries in the region have well-established healthcare systems and high demand for respiratory inhalers, others face barriers to access, limited healthcare infrastructure, and lower awareness of respiratory diseases. Initiatives to improve healthcare access, increase disease awareness, and enhance respiratory care services present opportunities for market growth in the Middle East and Africa.
Latin America completes the geographical segmentation of the global respiratory inhalers market, encompassing countries with diverse healthcare systems, cultural norms, and economic conditions. The region experiences a significant burden of respiratory diseases, particularly asthma and COPD, necessitating access to affordable and effective inhaler devices for disease management. Investments in healthcare infrastructure, expansion of respiratory care services, and efforts to address socioeconomic determinants of health contribute to the growth of the respiratory inhalers market in Latin America.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Respiratory Inhalers Market. These factors include; Market Drivers, Restraints, and Opportunities.
Drivers:
- Increasing prevalence of respiratory diseases
- Growing adoption of inhaler therapy
- Rising healthcare expenditure
- Aging population
-
Rising air pollution levels - Rising air pollution levels serve as a significant driver in the global respiratory inhalers market, compelling a heightened demand for effective respiratory care solutions. With industrialization, urbanization, and increased vehicular emissions, air pollution has become a pressing environmental issue worldwide. Fine particulate matter, pollutants, and allergens present in polluted air pose serious respiratory health risks, exacerbating symptoms for individuals with existing respiratory conditions such as asthma and COPD.
The escalation of air pollution levels correlates with a surge in respiratory ailments, prompting individuals to seek timely and efficient methods of managing their symptoms and safeguarding their respiratory health. In response to this escalating concern, there has been a noticeable uptick in the adoption of respiratory inhalers, which offer targeted delivery of medication directly to the lungs, providing rapid relief from respiratory distress caused by exposure to polluted air.
The detrimental impact of air pollution on respiratory health has propelled governments, healthcare providers, and advocacy groups to prioritize respiratory care initiatives and promote the use of inhaler therapy as a frontline defense against the adverse effects of air pollution. Public health campaigns and awareness programs underscore the importance of proactive respiratory management and adherence to prescribed inhaler regimens, empowering individuals to mitigate the risks associated with prolonged exposure to polluted air.
Restraints:
- Stringent regulatory requirements
- Patient adherence and technique errors
- Limited availability of respiratory healthcare professionals
- Adverse effects of inhaler medications
-
Challenges in accessing respiratory care in rural areas - Challenges in accessing respiratory care in rural areas pose a significant restraint in the global respiratory inhalers market, hindering the delivery of essential healthcare services to underserved populations. Rural communities often face geographical, infrastructural, and socioeconomic barriers that impede their access to quality respiratory care, exacerbating disparities in healthcare access and outcomes.
Geographical isolation and limited healthcare infrastructure in rural areas result in reduced availability of healthcare facilities, respiratory specialists, and diagnostic resources. This scarcity of healthcare resources makes it challenging for individuals in rural communities to access timely diagnosis, treatment, and management of respiratory conditions, leading to underdiagnosis and undertreatment of respiratory diseases.
Socioeconomic factors such as low income levels, limited health insurance coverage, and transportation barriers further compound the challenges faced by rural residents in accessing respiratory care services. Financial constraints may prevent individuals from seeking timely medical attention or obtaining prescribed inhaler medications, exacerbating their respiratory symptoms and reducing their overall quality of life.
Opportunities:
- Digital health innovations for remote monitoring
- Personalized medicine for respiratory conditions
- Collaboration between pharmaceutical and device companies
- Retail pharmacy expansion for better access
-
Awareness initiatives for respiratory health - Awareness initiatives for respiratory health present a significant opportunity in the global respiratory inhalers market, offering a proactive approach to improving public knowledge, promoting preventive measures, and encouraging early detection and management of respiratory conditions. These initiatives play a crucial role in raising awareness about the prevalence, risk factors, symptoms, and treatment options for respiratory diseases, empowering individuals to take proactive steps towards maintaining optimal respiratory health.
By educating the public about the importance of respiratory health, including the adverse effects of smoking, air pollution, and occupational hazards on lung function, awareness initiatives aim to prevent the onset of respiratory conditions and reduce the burden of respiratory diseases on individuals and healthcare systems. Public health campaigns, community workshops, and educational materials disseminated through various channels, including media, schools, workplaces, and healthcare facilities, serve as effective platforms for delivering key messages about respiratory health promotion and disease prevention.
Awareness initiatives for respiratory health play a pivotal role in promoting adherence to prescribed inhaler regimens and fostering self-management skills among individuals with respiratory conditions. By increasing understanding of the role of inhaler therapy in symptom management, disease control, and exacerbation prevention, these initiatives empower patients to take an active role in managing their respiratory health and adhering to recommended treatment plans.
Competitive Landscape Analysis
Key players in Global Respiratory Inhalers Market include,
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- CHIESI Farmaceutici S.p.A. (Italy)
- GlaxoSmithKline plc (U.K.)
- Propeller Health (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Beximco Pharmaceuticals Ltd. (Bangladesh)
- 3M (U.S.)
- Cipla Inc. (India)
- Koninklijke Philips N.V. (Netherlands)
- Merck & Co., Inc. (U.S.)
- Omron Healthcare, Inc. (Japan)
- Cohero Health, Inc. (U.S.)
- PARI GmbH (Germany)
- Glenmark Pharmaceuticals Limited (India)
- Senzer Ltd (U.K.)
- Novartis AG (Switzerland)
- HELTMAN Medikal A.S. (Turkey)
- Mundipharma International (U.K.)
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Devices
- Market Snapshot, By Product
- Market Snapshot, By Therapeutic Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Respiratory Inhalers Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing prevalence of respiratory diseases
- Growing adoption of inhaler therapy
- Rising healthcare expenditure
- Aging population
- Rising air pollution levels
- Restraints
- Stringent regulatory requirements
- Patient adherence and technique errors
- Limited availability of respiratory healthcare professionals
- Adverse effects of inhaler medications
- Challenges in accessing respiratory care in rural areas
- Opportunities
- Digital health innovations for remote monitoring
- Personalized medicine for respiratory conditions
- Collaboration between pharmaceutical and device companies
- Retail pharmacy expansion for better access
- Awareness initiatives for respiratory health
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Respiratory Inhalers Market, By Devices, 2021 - 2031 (USD Million)
- Nebulizers
- Compressed
- Mesh
- Ultrasonic
- Dry Powder Inhaler
- Multi-Unit Dose Inhaler
- Multi Dose Inhaler
- Single Unit Dose Inhaler
- Metered Dose Inhaler
- Nebulizers
- Global Respiratory Inhalers Market, By Product, 2021 - 2031 (USD Million)
- Dry Powder Inhaler
- Metered Dose Inhaler
- Others
- Global Respiratory Inhalers Market, By Therapeutic Application, 2021 - 2031 (USD Million)
- Asthma
- Chronic Obstructive Pulmonary Disease
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Global Respiratory Inhalers Market, By End Users, 2021 - 2031 (USD Million)
- Hospitals & Clinics
- Respiratory Care Center
- Academic and Research Institutes
- Others
- Global Respiratory Inhalers Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Respiratory Inhalers Market, By Devices, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- CHIESI Farmaceutici S.p.A. (Italy)
- GlaxoSmithKline plc (U.K.)
- Propeller Health (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Beximco Pharmaceuticals Ltd. (Bangladesh)
- 3M (U.S.)
- Cipla Inc. (India)
- Koninklijke Philips N.V. (Netherlands)
- Merck & Co., Inc. (U.S.)
- Omron Healthcare, Inc. (Japan)
- Cohero Health, Inc. (U.S.)
- PARI GmbH (Germany)
- Glenmark Pharmaceuticals Limited (India)
- Senzer Ltd (U.K.)
- Novartis AG (Switzerland)
- HELTMAN Medikal A.S. (Turkey)
- Mundipharma International (U.K.)
- Company Profiles
- Analyst Views
- Future Outlook of the Market